Not available
Quote | Ocular Therapeutix Inc. (NASDAQ:OCUL)
Last: | $6.69 |
---|---|
Change Percent: | -0.15% |
Open: | $6.69 |
Close: | $6.69 |
High: | $6.915 |
Low: | $6.6 |
Volume: | 867,181 |
Last Trade Date Time: | 07/03/2024 03:00:00 am |
News | Ocular Therapeutix Inc. (NASDAQ:OCUL)
2024-06-27 18:00:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-20 14:24:06 ET More on Ocular Therapeutix Ocular Therapeutix: Betting On Axpaxli For A Major Market Breakthrough Ocular Therapeutix: Unveiling Pipeline Progress (AXPAXLI, PAXTRAVA) And Q1 Results Ocular Therapeutix jumps after investor day updates Ocu...
Message Board Posts | Ocular Therapeutix Inc. (NASDAQ:OCUL)
Subject | By | Source | When |
---|---|---|---|
Tard sells $6.00 call option at $0.15 at | trendzone | investorshub | 02/14/2023 9:02:55 PM |
$OCUL..........................................https://stockcharts.com/h-sc/ui?s= | glenn1919 | investorshub | 02/14/2023 5:30:55 PM |
znewcar1: $OCUL 35% v27,1M c5.23 f77,010M H6.12 ML3.74 gapNgo 134 Views | znewcar1 | investorshangout | 02/14/2023 4:25:16 AM |
znewcar1: 9 views Mind blown. $OCUL 56% v16,8M C6.04 f77,010M H6.05 ML3.74 | znewcar1 | investorshangout | 02/13/2023 7:21:38 PM |
znewcar1: HOD5.99 push a little more for my target please! Thank you6.05 | znewcar1 | investorshangout | 02/13/2023 7:20:38 PM |
News, Short Squeeze, Breakout and More Instantly...
Ocular Therapeutix Inc. Company Name:
OCUL Stock Symbol:
NASDAQ Market:
Ocular Therapeutix Inc. Website:
2024-06-27 18:00:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
151 subjects enrolled in various stages of loading and randomization in SOL-1 pivotal study of AXPAXLI in wet AMD as of June 7, 2024 Announces plans for SOL-R study to evaluate repeat doses of AXPAXLI in wet AMD 48-week HELIOS NPDR results show 23.1% of patients in AXPAXLI arm e...
2024-06-07 11:52:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...